RU2373204C2 - Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h - Google Patents

Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h Download PDF

Info

Publication number
RU2373204C2
RU2373204C2 RU2006102510/04A RU2006102510A RU2373204C2 RU 2373204 C2 RU2373204 C2 RU 2373204C2 RU 2006102510/04 A RU2006102510/04 A RU 2006102510/04A RU 2006102510 A RU2006102510 A RU 2006102510A RU 2373204 C2 RU2373204 C2 RU 2373204C2
Authority
RU
Russia
Prior art keywords
ethyl
yloxy
benzothiazol
phenyl
phenoxy
Prior art date
Application number
RU2006102510/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006102510A (ru
Inventor
Фрэнк У. АКС (US)
Фрэнк У. АКС
Скотт Д. БЕМБЕНЕК (US)
Скотт Д. БЕМБЕНЕК
Кристофер Р. БАТЛЕР (US)
Кристофер Р. Батлер
Джеймс П. ЭДВАРДС (US)
Джеймс П. Эдвардс
Анн М. ФУРЬЕ (US)
Анн М. Фурье
Черил А. ГРАЙС (US)
Черил А. Грайс
Брэд М. САВАЛЛЬ (US)
Брэд М. Савалль
Кевин Л. ТАЙС (US)
Кевин Л. Тайс
Дзяньмэй ВЭЙ (US)
Дзяньмэй Вэй
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of RU2006102510A publication Critical patent/RU2006102510A/ru
Application granted granted Critical
Publication of RU2373204C2 publication Critical patent/RU2373204C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Structural Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2006102510/04A 2003-07-28 2004-07-27 Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h RU2373204C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
US60/490,710 2003-07-28

Publications (2)

Publication Number Publication Date
RU2006102510A RU2006102510A (ru) 2006-07-27
RU2373204C2 true RU2373204C2 (ru) 2009-11-20

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2006102510/04A RU2373204C2 (ru) 2003-07-28 2004-07-27 Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h
RU2006102508/04A RU2359970C2 (ru) 2003-07-28 2004-07-27 Производные бензимидазола, бензотиазола и бензоксазола и их применение в качестве модуляторов lta4h

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2006102508/04A RU2359970C2 (ru) 2003-07-28 2004-07-27 Производные бензимидазола, бензотиазола и бензоксазола и их применение в качестве модуляторов lta4h

Country Status (28)

Country Link
US (2) US20050043379A1 (enExample)
EP (2) EP1660492B1 (enExample)
JP (2) JP2007500703A (enExample)
KR (2) KR101149379B1 (enExample)
CN (2) CN100591679C (enExample)
AR (2) AR045729A1 (enExample)
AT (2) ATE405562T1 (enExample)
AU (2) AU2004261628B2 (enExample)
BR (2) BRPI0413072A (enExample)
CA (2) CA2534212A1 (enExample)
CY (1) CY1108560T1 (enExample)
DE (2) DE602004015620D1 (enExample)
DK (2) DK1660491T3 (enExample)
ES (2) ES2311858T3 (enExample)
HR (2) HRP20060041B1 (enExample)
IL (1) IL173372A (enExample)
MY (1) MY145080A (enExample)
NO (2) NO20060771L (enExample)
NZ (2) NZ544970A (enExample)
PL (2) PL1660492T3 (enExample)
PT (2) PT1660491E (enExample)
RU (2) RU2373204C2 (enExample)
SG (2) SG130192A1 (enExample)
SI (2) SI1660492T1 (enExample)
TW (2) TWI362383B (enExample)
UA (2) UA82888C2 (enExample)
WO (2) WO2005012297A1 (enExample)
ZA (2) ZA200601716B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100591679C (zh) * 2003-07-28 2010-02-24 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用
CN101189012A (zh) * 2005-03-31 2008-05-28 詹森药业有限公司 苯基和吡啶基lta4h调节剂
ES2523565T3 (es) 2005-04-13 2014-11-27 Astex Therapeutics Limited Derivados de hidroxibenzamida y sus usos como inhibidores de la hsp90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CA2620127A1 (en) * 2005-09-02 2007-03-08 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
UA101943C2 (ru) * 2005-09-21 2013-05-27 Декод Дженетикс Ехф Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
AU2006333522A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
CA2634701C (en) 2005-12-21 2014-07-29 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
HUE031972T2 (en) * 2005-12-29 2017-08-28 Celtaxsys Inc Diamine derivatives as inhibitors of leukotriene a4 hydrolase
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
US8299095B2 (en) * 2006-06-16 2012-10-30 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof
US7728032B2 (en) * 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
WO2008019302A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation
EP2066800A2 (en) * 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
US20100120807A1 (en) * 2007-03-08 2010-05-13 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2008120710A1 (ja) * 2007-03-30 2008-10-09 Panasonic Electric Works Co., Ltd. 活動強度計
UY31443A1 (es) * 2007-10-31 2009-04-30 Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
US20090176785A1 (en) * 2007-11-16 2009-07-09 Abbott Laboratories Method of treating arthritis
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
MX2010011154A (es) * 2008-04-11 2010-12-21 Janssen Pharmaceutica Nv Tiazolopiridin-2-iloxi-fenilo y tiazolopirazin-2-iloxifenilaminas como moduladores de la leucotrieno a4 hidrolasa.
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
AU2010249041B2 (en) 2009-05-14 2014-11-13 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
EP2776023B1 (en) 2011-10-25 2016-03-09 Janssen Pharmaceutica, N.V. Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
KR20150131211A (ko) * 2013-03-14 2015-11-24 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
WO2015094902A1 (en) * 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
RU2715897C2 (ru) 2015-06-09 2020-03-04 Эббви Инк. Модуляторы ядерных рецепторов
IL267352B2 (en) 2016-12-21 2023-10-01 Hoffmann La Roche Method for in vitro glycoengineering of antibodies
WO2018114878A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN113784713A (zh) * 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 白三烯合成抑制剂
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
TW202235071A (zh) * 2020-11-19 2022-09-16 美商特洛治療公司 小分子化合物及組成物
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1681728A3 (ru) * 1988-05-24 1991-09-30 Пфайзер Инк. (Фирма) Способ получени производных N-(бензтиазолил-2)амидов бензойной или тиазол-4-карбоновой кислоты

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
DK171349B1 (da) * 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
EP1062216A1 (en) * 1998-02-25 2000-12-27 Genetics Institute, Inc. Inhibitors of phospholipase a2
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
CN100591679C (zh) * 2003-07-28 2010-02-24 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
HRP20160373T1 (hr) * 2005-03-16 2016-05-06 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1681728A3 (ru) * 1988-05-24 1991-09-30 Пфайзер Инк. (Фирма) Способ получени производных N-(бензтиазолил-2)амидов бензойной или тиазол-4-карбоновой кислоты

Also Published As

Publication number Publication date
EP1660491A1 (en) 2006-05-31
RU2006102508A (ru) 2006-07-27
JP4726238B2 (ja) 2011-07-20
NO20060771L (no) 2006-04-21
CN1856490A (zh) 2006-11-01
PL1660491T3 (pl) 2009-01-30
NZ544938A (en) 2009-05-31
WO2005012297A9 (en) 2007-01-04
CA2534228A1 (en) 2005-02-10
BRPI0412345A (pt) 2006-10-03
CN100591679C (zh) 2010-02-24
WO2005012296A1 (en) 2005-02-10
SG129449A1 (en) 2007-02-26
US20050043378A1 (en) 2005-02-24
IL173372A0 (en) 2006-06-11
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
SG130192A1 (en) 2007-03-20
CN1860117A (zh) 2006-11-08
JP2007500703A (ja) 2007-01-18
EP1660491B1 (en) 2008-08-06
AU2004261610A1 (en) 2005-02-10
PT1660491E (pt) 2008-10-10
UA82888C2 (en) 2008-05-26
MY145080A (en) 2011-12-15
TW200520756A (en) 2005-07-01
US20050043379A1 (en) 2005-02-24
KR20060057593A (ko) 2006-05-26
JP2007500706A (ja) 2007-01-18
DE602004015620D1 (de) 2008-09-18
AR045730A1 (es) 2005-11-09
KR101149379B1 (ko) 2012-06-28
CY1108560T1 (el) 2014-04-09
UA87986C2 (uk) 2009-09-10
HK1092790A1 (en) 2007-02-16
ES2311858T3 (es) 2009-02-16
AU2004261628B2 (en) 2011-05-12
HRP20060039A2 (en) 2006-08-31
AU2004261610B2 (en) 2010-05-20
TWI362383B (en) 2012-04-21
AU2004261628A1 (en) 2005-02-10
HRP20060041A2 (en) 2006-11-30
DE602004016002D1 (de) 2008-10-02
TW200523255A (en) 2005-07-16
RU2006102510A (ru) 2006-07-27
BRPI0413072A (pt) 2006-10-03
SI1660491T1 (sl) 2009-02-28
NZ544970A (en) 2009-02-28
ATE405562T1 (de) 2008-09-15
ZA200601720B (en) 2007-11-28
DK1660492T3 (da) 2008-11-03
WO2005012297A1 (en) 2005-02-10
ES2313079T3 (es) 2009-03-01
ZA200601716B (en) 2007-05-30
EP1660492A1 (en) 2006-05-31
EP1660492B1 (en) 2008-08-20
ATE403654T1 (de) 2008-08-15
HK1090359A1 (en) 2006-12-22
RU2359970C2 (ru) 2009-06-27
IL173372A (en) 2010-11-30
PT1660492E (pt) 2008-11-13
KR20060054408A (ko) 2006-05-22
PL1660492T3 (pl) 2009-01-30
SI1660492T1 (sl) 2009-02-28
DK1660491T3 (da) 2008-11-10
NO20060823L (no) 2006-03-15
HRP20060041B1 (hr) 2014-06-06

Similar Documents

Publication Publication Date Title
RU2373204C2 (ru) Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h
US20080194630A1 (en) LTA4H modulators and uses thereof
BRPI0709589A2 (pt) novos compostos
EP1558250A1 (en) Gamma-aminoamide modulators of chemokine receptor activity
EP1868605A2 (en) Phenyl and pyridyl lta4h modulators
AU2003284165A1 (en) Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
US20080275035A1 (en) Nitroimidazole Compounds
US10577361B2 (en) Dopamine D3 receptor antagonists having a morpholine moiety
WO2008100635A1 (en) 1- [3- (monocyclic amino) propyl] - 4, 5, 6, 7-tetrahydro-1h-pyrazolo [4, 3-c] -pyridines as modulators of cathepsin s
MXPA06001122A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
MXPA06001121A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
HK1092790B (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
HK1090359B (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170728